Too Young for Breast Cancer? Not at this Conference
February 12, 2019 07:00 ET
|
Young Survival Coalition
New York, NY, Feb. 12, 2019 (GLOBE NEWSWIRE) -- The Young Survival Coalition (YSC) will host more than 600 young breast cancer survivors, co-survivors and healthcare providers in Austin, Texas,...
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
November 14, 2018 10:00 ET
|
Sermonix Pharmaceuticals LLC
Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo...
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer
October 09, 2018 10:00 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Leaving a Legacy When You’re Young with Cancer
December 15, 2017 08:00 ET
|
Young Survival Coalition
New York, NY, Dec. 15, 2017 (GLOBE NEWSWIRE) -- More than 250,000 women living in the U.S. today were diagnosed with breast cancer before their 41st birthday, and approximately 12,000 young women...
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
November 08, 2017 16:01 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended...
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
September 11, 2017 06:00 ET
|
Cascadian Therapeutics, Inc.
Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...
2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121
August 09, 2017 10:30 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
Living Beyond Breast Cancer to Host 10th Annual Conference on Metastatic Breast Cancer April 8-10
February 02, 2016 08:50 ET
|
Living Beyond Breast Cancer
PHILADELPHIA, Feb. 2, 2016 (GLOBE NEWSWIRE) -- Hundreds of people will convene here April 8-10, 2016 for the 10th annual Conference on Metastatic Breast Cancer presented by Living Beyond Breast Cancer...
Living Beyond Breast Cancer to post blogs on Metastatic Breast Cancer Awareness Day Oct. 13
October 08, 2015 15:52 ET
|
Living Beyond Breast Cancer
PHILADELPHIA, Oct. 8, 2015 (GLOBE NEWSWIRE) -- Through Living Beyond Breast Cancer's "Beyond the Breast" campaign, women and men are drawing attention to what it's like to live with metastatic (Stage...
New Metastatic Breast Cancer Resource Available
July 31, 2015 11:33 ET
|
Patient Advocate Foundation
HAMPTON, Va., July 31, 2015 (GLOBE NEWSWIRE) -- Even with 13,910 new metastatic breast cancer diagnoses each year, Patient Advocate Foundation (PAF), a national nonprofit dedicated to helping...